Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy (Q92306391)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

review article

1 reference

title

Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

3

Lorenzo Galluzzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

4

Guido Kroemer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

author name string

Eric Deutsch

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

Cyrus Chargari

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

publication date

29 July 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

28 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

page(s)

e452-e463

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

Image-guided radiotherapy: from current concept to future perspectives

28 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast:

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Controversies and challenges regarding the impact of radiation therapy on survival

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

The hallmarks of successful anticancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Modeling Tumor Immunology and Immunotherapy in Mice

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Chromosomal aberrations and mortality of x-irradiated mammalian cells: emphasis on repair

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Towards precision radiotherapy for use with immune checkpoint blockers.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Strategies for optimizing the response of cancer and normal tissues to radiation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Ionizing irradiation induces acute haematopoietic syndrome and gastrointestinal syndrome independently in mice

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation-induced fibrosis: mechanisms and implications for therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

TGF-β: the master regulator of fibrosis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Linking cellular stress responses to systemic homeostasis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

TGF-β: duality of function between tumor prevention and carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Immunogenic cell death in cancer and infectious disease

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

The danger from within: alarmins in arthritis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Critical role of RAGE and HMGB1 in inflammatory heart disease

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

CXC receptor 1 and 2 and neutrophil elastase inhibitors alter radiation-induced lung disease in the mouse

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Effect of total body irradiation on late lung effects: Hidden dangers

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4 FoxP3 regulatory T cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

The therapeutic activity of low-dose irradiation on experimental arthritis depends on the induction of endogenous regulatory T cell activity

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation Enhances Regulatory T Cell Representation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Emerging targets for radioprotection and radiosensitization in radiotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Consensus guidelines for the detection of immunogenic cell death

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Cytosolic DNA Sensing in Organismal Tumor Control

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Using immunotherapy to boost the abscopal effect

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Host type I IFN signals are required for antitumor CD8 T cell responses through CD8{alpha} dendritic cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

An Anti-Tumor Immune Response is Evoked By Partial-Volume Single Dose Radiation in Two Murine Models

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Sparing level Ib lymph nodes by intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Systematic Review: The Impact of Cancer Treatment on the Gut and Vaginal Microbiome in Women With a Gynecological Malignancy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

The immune contexture in cancer prognosis and treatment

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Prospective Immunophenotyping of CD8 T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation oncology: a century of achievements.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Low-Dose Irradiation Promotes Persistent Oxidative Stress and Decreases Self-Renewal in Hematopoietic Stem Cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiation oncology in the era of precision medicine.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(19)30171-8

7 January 2021

10.1016/S1470-2045(19)30171-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31364597 AND SRC:MED&resulttype=core&format=json

28 April 2020

1 reference